{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113762.1.4.1116.388",
  "meta": {
    "versionId": "4",
    "lastUpdated": "2018-04-03T15:48:57.000-04:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.388",
  "version": "20171129",
  "name": "No Adjuvant Hormonal Therapy Prostate",
  "status": "active",
  "date": "2017-11-29T01:00:05-05:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "compose": {
    "include": [
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "concept": [
          {
            "code": "1P",
            "display": "Performance Measure Exclusion Modifier due to Medical Reasons"
          },
          {
            "code": "2P",
            "display": "Performance Measure Exclusion Modifier due to Patient Reasons"
          },
          {
            "code": "4164F",
            "display": "Adjuvant (ie, in combination with external beam radiotherapy to the prostate for prostate cancer) hormonal therapy (gonadotropin-releasing hormone [GnRH] agonist or antagonist) prescribed/administered (PRCA)"
          }
        ]
      }
    ]
  }
}